Toggle light / dark theme

The role of the immune tumor microenvironment in shaping metastatic dissemination, dormancy, and outgrowth

Immune and stromal orchestration of the pre-metastatic niche👇

✅Priming distant organs before tumor cell arrival Primary tumors actively condition distant organs by releasing soluble factors, cytokines, and tumor-derived exosomes. These signals recruit monocytes and neutrophils and reprogram resident immune and stromal cells, initiating the formation of a pre-metastatic niche (PMN) that becomes permissive to future metastatic seeding.

✅Role of monocytes and macrophages Recruited monocytes differentiate into inflammatory or immunosuppressive macrophages depending on the local context. In organs such as the lung and liver, these cells promote extracellular matrix (ECM) remodeling, fibrotic deposition, and secretion of growth factors, creating a supportive scaffold for disseminated tumor cells (DTCs).

✅Neutrophils as niche architects Neutrophils contribute to PMN formation through the release of matrix metalloproteinases (MMPs), inflammatory cytokines, and neutrophil extracellular traps (NETs). These processes alter tissue architecture, enhance inflammation, and support tumor cell survival and reactivation.

✅Organ-specific niche specialization Different organs develop distinct PMNs. In the lung, inflammatory macrophages and neutrophils drive ECM remodeling and leukotriene signaling. In the liver, fibrosis, granulins, and chemokine-driven immune cell recruitment promote an immunosuppressive environment favorable for metastatic colonization.

✅Fate of disseminated tumor cells Once DTCs arrive, they face multiple outcomes. Some are eliminated by immune surveillance, others enter long-term dormancy, and a subset evades immunity to initiate metastatic outgrowth. ECM composition, immune pressure, and stromal signaling critically determine these divergent fates.

✅Dormancy and reawakening Dormant DTCs can persist in a latent state for prolonged periods. Changes in ECM remodeling, inflammatory signaling, or immune suppression can trigger their reawakening, leading to renewed proliferation and metastatic progression.

Tumor-derived aminopeptidase N promotes early stages of brain metastatic colonization

In this study, we identified the aminopeptidase CD13 as a key mediator in a subset of human BrMs originating from breast and lung cancers, with approximately 30% of samples exhibiting cancer cell-specific CD13 expression. Notably, this prevalence aligns with previous reports in breast and lung primary tumors. In BC, CD13 cancer cell expression was documented in 36% of patient samples analyzed, with higher rates in invasive ductal carcinoma,31 while in lung cancer, 35% of patients analyzed were positive for cancer cell CD13 expression.32 These observations suggest that CD13 expression is maintained during metastatic progression to the brain, underscoring its potential as a therapeutic target. Importantly, CD13 expression in primary lung cancer is associated with significantly reduced survival, with a similar trend in BC.31,32 Consistent with these data, we show here that patients with HER2+ BC with CD13high tumors have significantly poorer clinical outcomes. These findings emphasize the importance of stratifying patients by CD13 status to better assess both its prognostic significance and therapeutic potential.

To gain mechanistic insight into CD13 function, we employed murine BrM models from three primary origins (breast, lung, and melanoma) that recapitulate distinct stages of the metastatic cascade. Notably, only the breast-BrM model exhibited robust CD13 expression, suggesting that lung cancer and melanoma may rely on alternative, CD13-independent mechanisms to colonize the brain. CD13 knockdown in breast-BrM cells significantly prolonged survival and reduced metastatic seeding following intracardiac injection. This effect was less pronounced when cancer cells were introduced directly into the brain parenchyma (intracranial injection) or implanted at the primary site (MFP), underscoring CD13’s predominant role during the initial colonization phase of metastasis.

Both gain-and loss-of-function experiments confirmed CD13’s functional importance in metastatic seeding. CD13 has been described as a moonlighting enzyme with diverse cellular functions relevant to regulating metastasis,16,17 including ÎČ1 integrin recycling,21 cell migration,21 and activation of the MAPK and PI3K pathways.33 Based on our RNA-seq analysis, CD13 overexpression may further enhance metastatic efficiency through activation of Rho family GTPases and effectors that orchestrate cytoskeletal remodeling, endothelial cell adhesion, and transendothelial migration.34 These features position CD13 as a compelling anti-cancer target; indeed, CD13 inhibition has been explored in several therapeutic development efforts. However, no brain-permeable CD13 inhibitor has yet been approved worldwide for clinical use,16 representing a critical gap in the translational landscape.

Beta-2-Microglobulin Is Bad For Neurogenesis: What’s My Data? (6-Test Analysis)

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links/Affiliates:
Blood testing (where I get the majority of my labs): https://www.ultalabtests.com/partners/michaellustgarten.

Blood testing with LifeExtension.com: https://www.anrdoezrs.net/click-101614996-15750394

At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.

Clearly Filtered Water Filter: https://get.aspr.app/SHoPY

Epigenetic, Telomere Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6
M0&irgwc=1

China’s ‘Ethnic Specific’ Bio-Weapons Target Specific Races Based on DNA

đŸ„” Ready to give MASA a try? Get 25% off your first order: https://MASAChips.com/ROMAN

☕ Hunter’s Blend Coffee: https://ept.ms/Hunters.

🎬 Primetime: https://youtu.be/smbrx3iuUr0

Episode Resources:

đŸ”” Chinese 5-Year Plan:

https://ept.ms/3FFc6cq.

A New Alzheimer’s Target Emerges: Blocking One Protein Restores Memory in Mice

Researchers have identified a protein that links brain immune activity, metabolism, and amyloid clearance, suggesting a new way to enhance current Alzheimer’s treatments. Alzheimer’s disease can look like a set of grim headlines: soaring case counts, ballooning health care costs, and an aging pop

Mitochondrial specialization and signaling shape neuronal function

How neuronal function is shaped by mitochondria.

Despite the established links between mitochondrial dysfunction and neuronal disorders, the specialization of mitochondria to support the specific demands of neurons has been less extensively explored.

Proper mitochondrial positioning influences an array of neuronal functions and processes, from neurodevelopment through synaptic transmission, due to the participation of mitochondria as local ATP suppliers, Ca2+ sinks, and sites of neurotransmitter synthesis.

In neurons, mitochondria are also crucial for local translation in axons and dendrites, to which they provide both local ATP and mRNA transport. In this way, mitochondria emerge as centers for neuronal plasticity sciencenewshighlights ScienceMission https://sciencemission.com/Mitochondrial-specialization


Neurons are specialized cells designed to process information and transmit it, often across long distances. In many neurons, the axonal volume far exceeds the somato-dendritic volume, creating a need for long-range transport and local polarization mechanisms. In addition, action potential firing and restoration of ionic gradients, as well as dynamic changes in synaptic plasticity, further increase the energetic demands of neurons. In this review, we highlight the roles mitochondria play in vertebrate neuronal biology and how mitochondrial functionality is tuned to support the unique demands of neurons. We cover the influence of mitochondrial positioning, ATP generation and Ca2+ buffering on neuronal function, and explore the role of mitochondria in neurotransmitter metabolism and local protein translation.

Simple patch can make medications safer and more effective

Vancomycin is the antibiotic doctors reach for when almost nothing else will work. It’s used in hospitals for serious drug-resistant infections, or for when an infection is spreading through the patient’s bloodstream, but it’s also notoriously tricky to dose: too little and it won’t knock out the infection, too much and the patient risks kidney damage or even death. Up to 40% of patients receiving vancomycin develop an acute kidney injury.

Right now, dosage levels are monitored by repeated blood tests, an invasive and time-consuming process that can’t always give clinicians the data they need in time. Hoping to solve this issue, UNSW and international researchers working alongside Australian diagnostics company Nutromics developed a minimally invasive patch that tracks the antibiotic in patients every five minutes.

The team has published the results of a clinical trial in Nature Biotechnology, and say its success demonstrates that the major scientific and safety challenges have been solved.

/* */